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Abstract The E-vita open plus is a one-stage endoluminal
stent graft system used for treating complex aneurysms and
dissections of the thoracic aorta. The National Institute for
Health and Care Excellence (NICE), as a part of its Medical
Technologies Evaluation Programme (MTEP), selected this
device for evaluation and invited the manufacturer, JOTEC
GmbH, to submit clinical and economic evidence. King’s
Technology Evaluation Centre (KiTEC), an External
Assessment Centre (EAC) commissioned by the NICE,
independently critiqued the manufacturer’s submissions.
The EAC considered that the manufacturer had included
most of the relevant evidence for the E-vita open plus, based
on international E-vita open registry data for 274 patients,
but had provided only limited evidence for the comparators.
The EAC therefore conducted a systematic review and
meta-analysis of all comparators to supplement the infor-
mation, and found ten additional studies providing outcome
data for the three two-stage comparators. The EAC noted
that the cost model submitted by the manufacturer did not
include key complications during the procedures. The EAC
developed a new economic model incorporating data on
complications along with their long-term costs. The revised
model indicated that the E-vita open plus might not provide
cost savings when compared with some of the comparators
in the short-term (1 year), but would have high cost savings
in the long-term, from the second year onwards. The NICE
Medical Technologies Guidance MTG 16, issued in
December 2013, recommended the adoption of the E-vita
open plus in selected patients within the National Health
Service in England.
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Key Points for Decision Makers
Available evidence suggest that E-vita open plus for
treating complex aneurysms and dissections of the
thoracic aorta could remove the need for a second
procedure and the associated risk of serious
complications.
The E-vita open plus is estimated to generate cost
savings compared with current two-stage repair from
about 2 years after the procedure.
The estimated cost savings ranged from around
£21,850 to £28,160 across the two-stage repair
comparators at 10 years after the procedure.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) promotes the adoption of cost- and clinically-
effective medical devices and diagnostics by the National
Health Service (NHS) in England through the work of the
Medical Technologies Evaluation Programme (MTEP) and
Diagnostics Assessment Programme (DAP), which were
established in 2009. Manufacturers of medical devices and
diagnostics notify the NICE when their product meets the
eligibility criteria for entry to the programme. Technolo-
gies are selected for development of medical technologies
guidance by the NICE’s Medical Technologies Advisory
Committee (MTAC) if they have the potential to offer a
significant clinical benefit to patients and the NHS, at the
same or reduced cost when compared with current practice.
Once a technology has been selected, the NICE prepares a
scope outlining the population and outcomes for which the
manufacturer should submit clinical and economic evi-
dence. A NICE-funded External Assessment Centre (EAC)
independently critiques the submitted evidence and pre-
pares an assessment report. The EAC is also required to
provide additional evidence if there are gaps in evidence
submitted by the manufacturer. The MTAC uses the EAC
report, together with other sources of advice, to produce
guidance on the proposed technology [1, 2].
This article presents a summary of the EAC report for
the E-vita open plus for treating complex aneurysms and
dissections of the thoracic aorta and the development of
the NICE guidance. The article is one among the series of
NICE Medical Technology Guidance summaries pub-
lished in Applied Health Economics and Health Policy
[3–6].
2 Decision Problem
2.1 Disease Overview
Complex thoracic aortic disease encompasses acute (AAD)
and chronic type A dissections (CAD), as well as aortic
arch aneurysms (TAA) with or without involvement of the
ascending and descending aorta [7].
Aortic dissection results from a tear in the inner layer of
the wall of the aorta leading to blood entering and sepa-
rating the layers of the wall. Acute aortic dissections are
defined as those identified within the first 2 weeks after the
initial tear, and chronic dissections as those identified at
times greater than 2 weeks. Aortic dissection is classified
by its location and the extent of involvement of the thoracic
aorta. Stanford Type A dissection affects the ascending
aorta and may extend to the arch and descending thoracic
aorta. Stanford Type B dissection does not affect the
ascending aorta and typically involves the descending
thoracic aorta, distal to the origin of the left subclavian
artery. Approximately two-thirds of aortic dissections are
Stanford Type A. Patients with acute dissection typically
present with pain and are classed as emergencies due to the
risk of the dissection rupturing the wall of the aorta,
affecting the integrity of the aortic valve and, through
involvement of the origins of the coronary arteries,
affecting perfusion of the myocardium. Population-based
studies suggest an incidence of aortic dissection of at least
0.5–3.5 per 100,000 persons per year [8, 9]. Moreover,
21–26 % of patients with aortic dissections die prior to
hospital admission, and up to 58–68 % die prior to defin-
itive operative intervention [10, 11].
A thoracic aortic aneurysm results from weakening of
the aortic wall, leading to localised dilatation, and is a life-
threatening condition. Patients with thoracic aneurysms are
often asymptomatic until the aneurysm expands. The most
common presenting symptoms are pain and aortic rupture.
A ruptured aneurysm can cause severe internal bleeding,
which can rapidly lead to shock or death. The life expec-
tancy of untreated patients with aortic aneurysms is lim-
ited, with death occurring within 5 years from rupture and/
or associated diseases in more than 75 % of cases [12]. The
incidence of TAA rupture is 3.5 per 100,000 persons per
year [11]. TAAs that are now estimated to affect 10 of
every 100,000 elderly adults, and aneurysms of the
descending thoracic aorta account for approximately
30–40 % of these [13].
2.2 Current Treatment Options
The current treatment options are detailed on the NICE
website [14] and are summarized briefly below. The size,
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growth rate, location (including involvement of branch
vessels) and the presence or absence of rupture determines
the management of complex thoracic aortic disease.
Patients can often be managed using clinical and imaging
surveillance and best medical treatment, with surgery
reserved for larger diameter aortas, rapid rates of enlarge-
ment and aortic rupture.
In order to treat complex disease of the thoracic aorta,
three surgical methods can be used. Two of these methods
involve a two stage ‘elephant trunk’ procedure; both
approaches are similar in their first stage but use alternative
repair techniques for the second stage. During the first
stage, the ascending aorta and arch are repaired with a
vascular graft through a median sternotomy. This is often
combined with aortic root or other cardiac interventions.
During this procedure a free-floating extension of the arch
prosthesis (the elephant trunk) is positioned in the proximal
descending thoracic aorta. In one approach, the second
stage of the procedure may be undertaken as an endovas-
cular procedure during which a stent graft is inserted into
the proximal descending aorta with arterial access via the
femoral artery (thoracic endovascular aortic repair—TE-
VAR). In an alternative approach, a second surgical pro-
cedure may be scheduled some weeks or months later
during which the descending aorta is repaired by extending
the ‘elephant trunk’ through a lateral thoracotomy
approach. The third method involves ‘debranching’ of the
head and neck vessels from the aortic using a combination
of vascular grafts. This then allows an endoluminal stent
graft to be positioned in the aortic arch and descending
aorta as either a single- or two-stage hybrid repair.
2.3 E-Vita Device
The E-vita open plus is an endoluminal stent graft system
used for treating complex aneurysms and dissections of the
thoracic aorta, and is manufactured by JOTEC GmbH
(Hechingen, Germany). The device is a one-piece polyester
fabric tube which combines a conventional vascular graft
and an attached endovascular stent graft that allows
simultaneous treatment of the ascending aorta, the arch and
the descending aorta in one procedure. The E-vita open
plus is a single-use device with a shelf life of 2 years. It is
supplied sterile and pre-loaded in its delivery system. The
device is available in a range of sizes with varying diam-
eters and lengths. It is deployed using a delivery system
which consists of catheters and a positioning aid. A luer
connector is incorporated to permit flushing of the inner
guide catheter.
The E-vita open plus is used in a single-stage procedure
known as a ‘frozen elephant trunk’. The thoracic aorta is
surgically opened with access through a median sternot-
omy approach. The stent graft is deployed distally in the
descending aorta and the proximal vascular graft is surgi-
cally anastomosed to the ascending aorta. The distal stent
graft is a self-expanding device with nitinol springs
incorporated into the fabric, and is used to treat the
descending aorta. The deployment of the distal stent graft
is achieved through retraction of a retaining sheath. The
proximal vascular graft is then used to repair the ascending
aorta and arch in a standard surgical fashion.
2.4 National Institute for Health and Care Excellence
(NICE) Scope
The scope of the decision problem developed by the NICE
for E-vita open plus defined the patient population as
‘‘patients with aneurysms or dissections of the thoracic
aorta involving the ascending aorta, arch and descending
aorta (Stanford Type A)’’. Three comparators were iden-
tified for consideration, corresponding to the current
treatment options described above: two-stage open surgical
repair with vascular graft placement; two-stage repair with
open surgical graft placement in the ascending aorta and
arch, and endovascular stent graft placement in the
descending aorta; open surgical ‘debranching’ of the head
and neck vessels with endoluminal stent graft placement in
the aortic arch and descending aorta. The outcome mea-
sures specified for consideration were technical proce-
dure(s) completion and success; mortality; major
complications such as stroke, paraplegia, renal failure,
myocardial infarction and others that may delay discharge;
length of ICU stay; total length of stay; freedom from
further interventions; long-term survival rates; incidence of
junctional endoleak and device-related adverse events. The
scope also requested cost analysis for the E-vita open plus
compared with the three comparators from an NHS and
personal social services perspective. It also requested
consideration of certain subgroups: patients with acute
Type A dissection, chronic Type A dissection and degen-
erative aneurysm. People with connective tissue disorders,
in particular people with Marfan’s syndrome and Ehlers–
Danlos syndrome, are at an increased risk of developing an
aortic aneurysm or dissection and may present at a younger
age. This group was identified as being in need of special
considerations, including issues of equality.
3 External Assessment Centre (EAC) Review
The first part of the manufacturer’s submission included
clinical evidence, comprising an overview of the disease
and current treatment provision, and a systematic review of
clinical evidence related to E-vita open plus and the
comparators. The second part was a submission of the
economic evidence comprising a systematic review of
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economic evidence and a de novo economic model of
E-vita open plus and the comparators. King’s Technology
Evaluation Centre (KiTEC), an EAC based in the King’s
Health Partners Academic Health Science Centre (KHP),
was commissioned by the NICE to critique the manufac-
turer’s submission of clinical and economic evidence. The
EAC was required to produce a structured assessment
report. Nominated expert advisers were available to pro-
vide advice to the EAC during the preparation of the report.
3.1 Clinical Effectiveness Evidence
The EAC considered that the sponsor’s search strategy for
clinical evidence relating to the E-vita open plus was
comprehensive, but that not all available evidence relating
to the comparators had been captured.
The sponsor reported finding 18 published studies on the
E-vita open plus, of which 13/18 studies were initially
reported as being relevant [7, 15–26]. The sponsor subse-
quently excluded 10/13 studies (for reasons discussed
below), leaving just 3 for inclusion [7, 15, 16]. All 3 of
these studies were descriptive, and none included
comparators.
The paper by Jakob et al. [7] was the most compre-
hensive, and was based on predecessor technology known
as the E-vita open stent. This was similar in design to
E-vita open plus, except that the latter is blood-tight and
does not require the addition of fibrin glue to seal the stent
graft. This paper reported on the International E-vita open
registry and provided data from January 2005 to December
2010 [7], including 274 patients with complex aortic dis-
ease who were enrolled in the registry. The majority were
male (74 %) and mean age was 60 years. At the time of
publication of Jakob’s study [7], the registry included eight
referral centres in Europe—Barcelona, Birmingham,
Bologna, Essen, Graz, Leipzig, Prague and Vienna—and
the maximum follow-up period was 6 years.
Jakob et al. [15] also reported on patients from the
International E-vita open registry, including patients
receiving surgery between January 2005 and March 2011, a
3-month longer time span than Jakob et al. [7]. However,
Jakob et al. [15] only included patients from the Essen
(Germany) centre (77 patients), a subset of the entire reg-
istry. The study by Hoffman et al. [16] was a small study
with short follow-up and limited outcome data and there-
fore was not useable.
3.1.1 Critique of Clinical Effectiveness Evidence
In summarising clinical evidence for the E-vita open plus,
the sponsor focussed on the results published in Jacob et al.
[7]. The EAC agreed with this decision, since the majority
of other articles were subsets of the International E-vita
open registry, and so their data largely overlapped with the
data in Jakob [18–21]. For other excluded papers it was
unclear whether they overlapped with Jacob et al. [7] as
reporting details were limited, but it was judged to be
likely, and therefore the EAC considered that they had
been correctly excluded [23–26]. One further paper was
excluded because the patient group was very small
(3 patients) [17], and another because it reported an animal
study [25]. The EAC identified a conference abstract [27]
that was not cited by the sponsor, but subsequent identifi-
cation of the full paper revealed that it was a subset of the
International E-vita open registry data and was therefore
not included.
The comparator studies only described outcomes in
patients who had undergone two-stage open surgical repair
with vascular graft replacement [28–31]. These studies
were observational, and all were from the US (New York;
Cleveland, OH; and Houston, TX), while the E-vita open
evidence was all from Europe. The comparator studies
were all conducted between 1990 and 2006, and therefore
most of the evidence preceded establishment of the E-vita
open registry. The EAC conducted a systematic review on
the three comparators to provide a complete picture of the
evidence and and found 10 additional studies. These
additional studies were then included in a meta-analysis of
all relevant outcomes. Full details of the meta-analyses are
given in the online report [32] but the EAC notes here that
the descriptive nature of the published papers, without
measures of precision such as confidence intervals, limited
secondary analysis on outcomes, and specifically pre-
sented long-term survival data being pooled across
studies.
3.2 Cost Evidence
The details of the cost evidence submitted by the manu-
facturer are presented in this section. The manufacturer
provided details of the search strategy used to identify
economic studies related to E-vita open plus and reported
that ‘‘health economics studies are not known and certainly
would not have been widely carried out prior to the ana-
lysis reported here for this new and innovative product’’.
However, the manufacturer did not provide a search
strategy related to the comparators.
The manufacturer provided a decision-tree model using
2012 prices, from the NHS and personal social services
perspective, for estimating the cost of E-vita open plus
along with four comparators (‘woven graft’ or ‘branched
graft’ during the first stage, followed by ‘woven graft’ or
‘endovascular stent’ during the second stage). With the
exception of ‘branched graft’ during first stage, followed
by ‘woven graft’ during the second stage, these mapped
with the three comparators listed in the scope. The ‘woven
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graft’ referred to two-stage open surgical repair, and
‘branched graft’ referred to open surgical ‘debranching’ of
the head and neck vessels with endoluminal stent graft
placement in the aortic arch.
The structure of the model used a cohort approach. It
was estimated that there would be 3,500 patients every year
with aortic arch problems in the UK, and that there would
be a 40 % adoption of E-vita open plus. The remaining
60 % of patients would either receive a ‘woven graft’
(15 %) or a ‘branched graft’ (85 %). The decision arm for
E-vita open plus modelled in-hospital and 30-day mortality
at 15 % and assumed the remaining 85 % of patients to
have a positive outcome. Major complications such as
stroke, paraplegia and renal failure, which has long-term
cost implications, were not modelled for the E-vita open
plus or the comparators.
Mortality rates with the E-vita open plus and the com-
parators were based on the studies identified in the clinical
evidence section. Mortality rates for the E-vita open plus
(15 %) were based on the international E-vita open registry
publication [7]. The mortality rates for stage 1 for the
comparators were not modelled. Stage 2 mortality rates of
20 % (woven graft option) and 30 % (branched graft
option) were assumed. The time horizon of the economic
model was 1 year. The manufacturer did not include any
long-term outcomes, citing limited information on long-
term mortality rates for the E-vita open plus and the
comparators. No subgroup analysis was performed.
The manufacturer had undertaken a bottom-up approach
for costing the technology and comparators. The important
data sources for cost included the annual Personal Social
Services Research Unit (PSSRU) unit cost compendium
[33], NHS reference costs [34] and other literature. The
cost of the stents was sourced from current suppliers, and
the cost of the E-vita open plus was the company’s target
price.
The manufacturer reported the average cost per patient
for the E-vita open plus (£25,688) and for all comparators
combined (£30,241), resulting in a saving of £4,552 for the
E-vita open plus. Adoption of the technology and com-
parators combined was assumed to be 100 %, and was
averaged across the 3,500 patients. This approach showed
differences when the individual procedure costs were
considered. For example, E-vita open plus, woven graft
(stage 1) with woven graft (stage 2), woven graft (stage 1)
with endovascular stent (stage 2), branched graft (stage 1)
with woven graft (stage 2) and branched graft (stage 1)
with endovascular stent (stage 2) showed costs of £24,480,
£35,216, £26,691, £36,016 and £27,491, respectively.
Sensitivity analyses also revealed that the E-vita open plus
has cost savings, even with varied levels of adoption,
varied suitability for second stage in the comparator pro-
cedures, and varied in-hospital death rates. The
manufacturer concluded that the E-vita open plus is supe-
rior to its comparators.
3.2.1 Critique of Cost Evidence
The EAC’s critique of the cost evidence submitted by the
manufacturer is presented in this section. The search
strategy for economic evidence had a number of flaws: the
search was performed well before the scope was issued and
needed updating; only EMBASE and the Cochrane data-
base of systematic reviews were included; no search was
conducted on the comparators. The EAC undertook a new
search for economic evidence related to the technology and
comparators on MEDLINE, MEDLINE(R), EMBASE,
Econlit, NHS Economic Evaluation Database (EED) and
the Health Technology Assessment (HTA) database. The
EAC did not find any relevant evidence related to the
E-vita open plus or the comparators, and concluded that
there is no published economic evidence.
The manufacturer assumed a cohort of around 3,500
patients with aortic arch problems, who could benefit from
the technology. However, the EAC considered that this
number could be an overestimate since NICE experts
foresee that only 50–100 people per year in England
would be suitable for treatment with the E-vita open plus.
Furthermore, for a cost-consequence analysis, the per
patient cost is more relevant than a cohort approach. The
decision arm for the E-vita open plus modelled in-hospital
and 30-day mortality at 15 % and assumed the remaining
85 % to have a positive outcome. The EAC considered
that this was not appropriate as patients could develop
major complications such as stroke, paraplegia and renal
failure. The cost model needed to incorporate these
complications as they will have cost implications, partic-
ularly in the longer term. The decision arm for the com-
parators also modelled only those patients suitable for a
stage 2 procedure, but had not incorporated complications
such as stroke, paraplegia and renal failure during stage 1.
Only stage 2 mortality rates of 20 % (woven graft option)
and 30 % (branched graft option) were assumed for the
comparators. From the evidence presented by the manu-
facturer, it was difficult to ascertain the basis of the
assumed stage 2 mortality rates.
In addition to the above concerns, there were issues with
the cost estimates used in the model. The cost of the sur-
geon, as given in the PSSRU document, was only £172/h
and not £399/h as used by the manufacturer [33]. The
anaesthetist cost was valued at registrar level and should
have been at consultant level. NHS reference costs [34] for
adult critical care and elective inpatient excess bed day for
aortic or abdominal surgery should have been used for ICU
and surgical ward cost per day, respectively. The cost of
cancer deaths within the NHS of £8,000 was assumed for
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the technology and comparators, which the EAC consid-
ered was not appropriate.
Given these issues, the EAC revised the cost model
using 2012 prices with updated assumptions based on lit-
erature sourced from the additional systematic review of
clinical evidence. The E-vita open plus was compared with
three comparators (two-stage with vascular graft, two-stage
with endovascular stent graft, open ‘debranching’ with
endoluminal stent graft), as specified in the scope. The
revised decision model was created incorporating compli-
cations and in-hospital mortality at each stage of the pro-
cedure for the technology and comparators, from the NHS
and personal social services perspective. The important
complications modelled were stroke, paraplegia, renal
failure and bleeding, along with in-hospital mortality.
Probabilities were based on the results of the systematic
review and meta-analysis of clinical evidence performed
by the EAC (Table 1). Cost estimates included in the cal-
culations were sourced from the PSSRU compendium,
NHS reference costs and literature [7, 28, 33–36]
(Table 1). E-vita open plus has only one stage and hence
the short-term model terminated after outcomes of stage 1
had occurred. The comparators were all two-stage proce-
dures, and outcomes were modelled at each stage. Those
with ‘no complications’ and ‘bleeding’ in stage 1 were
assumed to move on to stage 2 for all the comparators. All
the other outcomes, such as stroke, paraplegia, renal failure
and in-hospital mortality, terminated at stage 1. The time
horizon for the short-term model was 1 year since most of
the two-stage procedures were expected to be completed
within 6 months [28–31].
In the long-term model, the lifetime cost of stroke,
paraplegia and renal failure were modelled separately and
added to the decision model to estimate the expected cost.
The time horizon for the lifetime cost was 20 years. This
was based on the average age of 65 years of patients in the
included studies [7, 28–31, 35–39] and life expectancy at
65 years for the UK population, which is around 20 years
[40]. Annual costs of care for stroke, paraplegia and renal
failure were sourced from published literature [41–43] and
discounted at 3.5 % per annum. The discounted annual cost
was multiplied with survival probability for 65–85 years,
estimated using background mortality rate from UK life
tables multiplied with a standard mortality ratio of 2 for
stroke, paraplegia and renal failure [44–46]. The weighted
annual costs were summed to estimate the lifetime cost of
the complications.
The base-case expected cost in the short-term and long-
term is presented in Table 2. In the short-term, the E-vita
open plus showed little cost savings (£280) compared with
two-stage repair with vascular graft. However, the E-vita
open plus was cost-incurring in the short-term when
compared with two-stage repair with endovascular stent
graft (£4,760) and open ‘debranching’ with endoluminal
stent graft (£7,663). When lifetime costs of complications
were modelled, the expected cost of the E-vita open plus
was lower than all the comparators, providing high cost
savings for the E-vita open plus in the long-term, from the
second year after surgery onwards. After 20 years, there
were savings of £41,213 when compared with two-stage
repair with vascular graft, £39,392 when compared with
two-stage repair with endovascular stent graft, and £51,778
when compared with open ‘debranching’ with endoluminal
stent graft.
In a deterministic sensitivity analysis, a number of
variables with uncertainty were varied. The variables
included in the sensitivity analysis were in-hospital mor-
tality; probability of paraplegia (for the E-vita open plus);
length of ICU stay; cost of ICU; cost of managing com-
plications; and annual cost of stroke, paraplegia and renal
failure. Sensitivity analysis for the probability of in-hos-
pital mortality and paraplegia (for the E-vita open plus) did
not alter the cost savings conclusions from those in the
base-case estimate. The length of ICU stay seemed to
affect the result in the short-term. When the ICU stay was
20 % of the total length of stay, all the comparators were
cost saving compared with the E-vita open plus. When it
was 60 % of the total length of stay, the conclusions were
the same as the base-case estimates but with higher cost
savings of £2,297 compared with the two-stage repair with
vascular graft procedure. The cost of ICU also affected the
results in a similar way to the proportion of ICU stay in the
short-term. However, neither the length of ICU stay nor the
associated cost of ICU affected the cost saving found in the
base-case estimate for the E-vita open plus in the long-
term. Varying the cost of managing complications did not
change the conclusions from the base-case estimate. Fur-
thermore, varying the annual cost of stroke, paraplegia and
renal failure did not change the conclusions on cost savings
for the E-vita open plus in the long-term. Hence, the E-vita
open plus remained a cost-saving procedure in the long-
term when compared with all comparators.
3.3 Conclusion of the EAC
The manufacturer submitted clinical evidence regarding
the E-vita open plus. All of the published evidence on the
E-vita open plus was included. However, the manufacturer
submitted clinical evidence related to only one compara-
tor—two-stage vascular graft using classical elephant trunk
procedure. Two other comparators (two-stage with endo-
vascular stent graft and open ‘debranching’ with endolu-
minal stent graft) listed in the scope were not included. The
EAC performed a new systematic review and found studies
relating to the other two comparators. Meta-analyses were
undertaken with outcomes from the included studies to
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provide pooled estimates of all key outcomes, including
complications.
The EAC also performed a new search, which confirmed
the manufacturer’s finding that there was no published
economic evidence related to the E-vita open plus and
comparators. In the de novo cost model submitted by the
manufacturer, only various levels of adoption, suitability
for second-stage procedures, and in-hospital mortality were
modelled by the manufacturer. The EAC considered that
other complications (and their associated lifetime costs)
such as stroke, paraplegia, renal failure and bleeding
should be included in the model. Furthermore, the EAC felt
that some of the manufacturer’s assumptions could be
improved upon. With the results and probabilities from the
meta-analysis, the EAC revised the cost models with some
changes in the assumptions. The results of the revised
model shows that the E-vita open plus might not provide
significant cost savings when compared with some of the
comparators in the short-term, but will nonetheless have
high cost savings in the long run. The cost difference in the
short-term is driven by the high technology costs and
longer stay in hospital. Since E-vita open plus is a single-
stage procedure and the comparators are all two-stage
procedures, the probability of complications is greater for
Table 1 Probabilities and costs for technology and comparators
E-vita open plus Two-stage with
vascular graft
Two-stage with
endovascular stent
graft
Open debranching with
endoluminal stent graft
Stage 1 Stage 1 Stage 2 Stage 1 Stage 2 Stage 1 Stage 2
Probabilities
Complications (bleeding) 0.139 0.046 0.037 0.042 0.056 0.081 0
Complications (stroke) 0.058 0.034 0.039 0.074 0 0.081 0.037
Complications (paraplegia) 0.08 0.042 0.041 0.042 0.078 0.025 0
Complications (renal failure) 0.036 0.085 0.06 0.125 0 0.182 0
Mortality (in-hospital) 0.15 0.085 0.08 0.089 0.096 0.135 0.037
Costs
Operating time (h) 7.5 7 5 7 2.5 6 2
Operating time (range, h) (4.5–13.5) (4–13) (3–7) (4–13) (1.2–4.5) (3–10) (1.2–5)
Total length of stay (days) 19 16 17 16 6 14 6
Total length of stay (range, days) (12–29) (9–20) (12–25) (9–20) (4–10) (9–20) (4–10)
ICU days (40 %) 8 6 7 6 2 6 2
Surgical ward days (60 %) 11 10 10 10 4 8 4
Cost of surgery (£)
Consultant surgeon (1) @ £172/h 1,290 1,204 860 1,204 430 1,032 344
Consultant anaesthetist (1) @ £172/h 1,290 1,204 860 1,204 430 1,032 344
Associate specialist (1) @ £131/h 983 917 655 917 328 786 262
Perfusionist (1) at registrar’s rate £86/h 645 602 430 602 215 516 172
Specialist nurse (2) @ £100/h 1,500 1,400 1,000 1,400 500 1,200 400
Consultant radiologist (medical) @ £157/h 393 314
Cost of E-vita open plusa 10,500
Cost of woven grafta 200 200 200
Cost of branched grafta 1,000
Cost of endovascular stent grafta 5,000 5,000
Other consumablesa 130 130 130 130 130 130 130
Cost of complications management @ £2,155 2,155 2,155 2,155 2,155 2,155 2,155 2,155
Cost of ICU @ £1,410/day (range £870–£2,000) 10,716 9,024 9,588 9,024 3,384 7,896 3,384
Cost of surgical ward @ £383/day 4,366 3,677 3,907 3,677 1,379 3,217 1,379
Total cost (with complication) [£] 33,575 20,513 19,785 20,513 14,343 18,964 13,884
Total cost (without complication) [£] 31,420 18,358 17,630 18,358 12,188 16,809 11,729
ICU intensive care unit
a Source: JOTEC GmbH submission
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the comparators, which has implications for lifetime costs
and provides cost savings in the longer term for the E-vita
open plus device.
4 NICE Guidance
In line with the MTEP process, the MTAC met to develop
draft recommendations following which a medical tech-
nology consultation document was produced. Comments
were accepted by the NICE on these draft recommenda-
tions as well as notification of inaccuracies and additional
information. Following a consultation period, comments
were collated and presented to the MTAC for discussion.
4.1 Draft Recommendations
The MTAC met in July 2013 and, following review of the
manufacturer’s submissions and the EAC report [32],
together with evidence from expert advisers, the following
provisional recommendations were made:
1. ‘‘The case for adopting the E-vita open plus for
treating complex aneurysms and dissections of the
thoracic aorta, in a carefully selected group of people,
is supported by the evidence.
2. Using the E-vita open plus could remove the need for a
second procedure and the associated risk of serious
complications, and it should therefore be considered
for people:
• who would otherwise need a two-stage repair
procedure because their aortic disease extends into
or beyond the distal part of their aortic arch (into
the proximal descending aorta), but
• who would not need additional intervention (such
as stent grafting) in the descending aorta.
3. The E-vita open plus is estimated to generate cost
savings compared with the current two-stage repair
from about 2 years after the procedure. The estimated
cost saving per patient at 5 years after the procedure is
around £13,800 when compared with two-stage repair
involving open insertion of a vascular graft, £9,850
when compared with two-stage repair involving endo-
vascular stent grafting and £12,000 when compared
with open surgical debranching followed by endolu-
minal stent grafting. At 10 years after the procedure,
the estimated cost savings ranged from around £21,850
to £28,160 across the three comparators.’’
4.2 Consultation Response
The NICE received few (i.e. not many) comments during
the public consultation period, the most important one
being that new evidence on the E-vita open plus was
identified [47]. The EAC reviewed this new paper to
determine whether there were any substantive differences
from the evidence provided in earlier literature. Jakob et al.
[7] reported results from the E-vita open registry for the
period January 2005 to December 2010, including 274
patients. The new evidence [47] reported results from the
same registry for a longer period—January 2005 to October
2012, including 416 patients. Comparison of outcome data
in the two papers revealed no important differences in the
Table 2 Expected cost and savings of technology and comparators (£)
E-vita open plus Two-stage with vascular
graft
Two-stage with endovascular
stent graft
Open debranching with
endoluminal stent graft
(Technology) Comparator 1 Savings Comparator 2 Savings Comparator 3 Savings
Expected cost (short-term) 32,417 32,697 -280 27,657 4,760 24,755 7,663
Expected cost (long-term)
Year l 35,267 38,538 -3,271 33,733 1,534 31,948 3,319
Year 2 37,920 43,976 -6,057 39,391 -1,471 38,646 -726
Year 3 40,478 49,222 -8,743 44,847 -4,368 45,106 -4,627
Year 4 42,943 54,273 -11,331 50,102 -7,159 51,327 -8,384
Year 5 45,316 59,139 -13,822 55,164 -9,847 57,320 -12,003
Year 6 47,601 63,822 -16,221 60,036 -12,434 63,087 -15,486
Year 7 49,802 68,333 -18,531 64,728 -14,926 68,643 -18,841
Year 8 51,919 72,673 -20,754 69,243 -17,324 73,988 -22,069
Year 9 53,956 76,849 -22,893 73,587 -19,631 79,131 -25,175
Year 10 55,913 80,860 -24,948 77,760 -21,847 84,071 -28,158
Year 15 64,563 98,592 -34,029 96,206 -31,643 105,909 -41,346
Year 20 71,406 112,619 -41,213 110,797 -39,392 123,184 -51,778
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overall estimates for in-hospital mortality, stroke and
paraplegia, and therefore the EAC saw no necessity to
change the assumptions in the cost model. In summary, the
EAC considered that the original modelling, based on the
2011 outcomes, remained valid and appropriate.
4.3 Final Guidance
The MTAC considered the results of the consultation, and
the final Medical Technology Guidance document for the
E-vita open plus for treating complex aneurysms and dis-
sections of the thoracic aorta was published by the NICE
on 18 December 2013 [14]. There were no changes to the
provisional recommendations, and the final guidance was
substantially the same as the draft, except for some small
changes to the description of the insertion procedure.
5 Challenges
Several challenges were encountered when reviewing and
using the clinical evidence for this technology. First, the
levels of statistical analysis and reporting in the published
papers were quite basic, such that estimates were given
without measures of precision or variability. This made it
difficult to interpret estimates and, in some cases, impos-
sible to incorporate them into meta-analyses; for example,
when analysing long-term survival with estimates given as
percentages without confidence intervals. A second chal-
lenge was the comparison of the single-stage outcomes for
the E-vita open plus with the two-stage comparators. This
was not straightforward as data for the two stages was not
always clearly presented and not all subjects were
accounted for. Therefore, it was difficult, if not impossible,
to calculate a single estimate of, for example, mortality
from the data that were reported in the literature. Other
challenges to interpretation of clinical study data arise from
the absence of randomised controlled trials making a direct
comparison between the E-vita open plus and any of its
comparators. Thus, all comparisons were of necessity
indirect, which carries the risk of bias in the resultant
estimates if the studies are not comparable. This difficulty
is seen in this assessment by between-study differences in
the time and place of the studies. The EAC noted that the
comparator studies mostly preceded the E-vita open plus
studies according to their date of publication and, further-
more, the comparator studies were all conducted in the US
whereas the E-vita open plus studies were all conducted in
Europe. In addition, data on the E-vita open plus were
predominantly based on its predecessor technology, E-vita
open stent. The two are similar in design but the E-vita
open plus is blood-tight and does not require the addition of
fibrin glue to seal the stent graft. From the baseline patient
information presented in the papers, there was no reason to
suspect that the patient populations in the E-vita open plus
studies were markedly different from those included in the
comparator studies. Hence, the EAC judged that, in the
absence of any direct comparator trial data, estimates from
separate studies, i.e. effectively indirect comparisons,
should be used in order to make best use of the evidence
that was available.
There were several challenges and learning points
associated with the revised cost model. Long-term data on
complications and health states were not available from the
literature. In the revised model, all complications were
assumed to occur in the short-term, i.e. shortly after the
procedure. Complications occurring in the longer term are
likely to be rare but will still have cost implications.
Decision analytic models were used in the analysis. This
was considered appropriate given the questions that were
addressed and the data availability, but more sophisticated
models (e.g. Markov models, discrete event simulations)
may allow for more refined analyses of the cost conse-
quences of the intervention. The EAC relied on determin-
istic rather than probabilistic sensitivity analyses, again
largely as a result of data limitations, to inform parameter
distributions. Review of clinical evidence from the manu-
facturer supplemented by the systematic review carried out
by the EAC revealed that data were available for tech-
nology subgroups only and were not available for the
comparators. Hence, subgroup analysis of the cost model
could not be performed. All complications were assumed to
occur separately, but this does not exclude the possibility
that, in some individuals, multiple complications may
occur. Finally, the implications of using multiple stents
during procedures were not included in the cost analysis
due to the lack of evidence.
6 Conclusion
Medical technology assessment is challenging due to lim-
itations in the quantity and appropriateness of the evidence
base available. The EAC, while fully acknowledging these
challenges, has shown how all available evidence may be
used to inform decision making and allow guidelines for
best clinical practice to be established.
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